A spotlight on the interplay between Wnt/β-catenin signaling and circular RNAs in hepatocellular carcinoma progression.
Wnt signaling
circRNA
hepatocellular carcinoma
mechanism
non-coding RNA
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
17
05
2023
accepted:
15
06
2023
medline:
7
8
2023
pubmed:
7
8
2023
entrez:
7
8
2023
Statut:
epublish
Résumé
Hepatocellular carcinoma (HCC) is one of the deadliest cancers due to multifocal development and distant metastasis resulting from late diagnosis. Consequently, new approaches to HCC diagnosis and treatment are required to reduce mortality rates. A large body of evidence suggests that non-coding RNAs (ncRNAs) are important in cancer initiation and progression. Cancer cells release many of these ncRNAs into the blood or urine, enabling their use as a diagnostic tool. Circular RNAs (CircRNAs) are as a members of the ncRNAs that regulate cancer cell expansion, migration, metastasis, and chemoresistance through different mechanisms such as the Wnt/β-catenin Signaling pathway. The Wnt/β-catenin pathway plays prominent roles in several biological processes including organogenesis, stem cell regeneration, and cell survival. Aberrant signaling of both pathways mentioned above could affect the progression and metastasis of many cancers, including HCC. Based on several studies investigated in the current review, circRNAs have an effect on HCC formation and progression by sponging miRNAs and RNA-binding proteins (RBPs) and regulating the Wnt/β-catenin signaling pathway. Therefore, circRNAs/miRNAs or RBPs/Wnt/β-catenin signaling pathway could be considered promising prognostic and therapeutic targets in HCC.
Identifiants
pubmed: 37546393
doi: 10.3389/fonc.2023.1224138
pmc: PMC10403753
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1224138Informations de copyright
Copyright © 2023 Mafi, Rismanchi, Malek Mohammadi, Hedayati, Ghorbanhosseini, Hosseini, Gholinezhad, Mousavi Dehmordi, Ghezelbash, Zarepour, Taghavi, Asemi, Alimohammadi and Mirzaei.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Cell Death. 2009 Sep 07;2:9-23
pubmed: 26124677
Clin Chim Acta. 2020 Jan;500:10-19
pubmed: 31604064
Oncotarget. 2017 Apr 6;8(35):58405-58416
pubmed: 28938566
Free Radic Biol Med. 2014 Apr;69:338-47
pubmed: 24509161
Eur Rev Med Pharmacol Sci. 2020 Aug;24(16):8359-8366
pubmed: 32894542
Eur Rev Med Pharmacol Sci. 2018 Jan;22(1):118-126
pubmed: 29364478
J Exp Clin Cancer Res. 2022 Sep 7;41(1):267
pubmed: 36071480
Mol Med Rep. 2016 Jun;13(6):4872-8
pubmed: 27082503
J Physiol Pharmacol. 2018 Apr;69(2):
pubmed: 29980141
RNA Biol. 2015;12(4):381-8
pubmed: 25746834
Semin Oncol. 2017 Jun;44(3):198-203
pubmed: 29248131
Cancers (Basel). 2018 Aug 02;10(8):
pubmed: 30072625
Front Pharmacol. 2022 Jan 11;12:784801
pubmed: 35087404
Semin Cancer Biol. 2011 Feb;21(1):44-58
pubmed: 21182948
BMC Syst Biol. 2016 Aug 01;10 Suppl 2:44
pubmed: 27490822
Nat Struct Mol Biol. 2015 Mar;22(3):256-64
pubmed: 25664725
Onco Targets Ther. 2020 Sep 22;13:9351-9364
pubmed: 33061423
Int J Mol Sci. 2019 Aug 13;20(16):
pubmed: 31412535
J BUON. 2020 May-Jun;25(3):1368-1374
pubmed: 32862578
Med Sci Monit. 2019 Feb 19;25:1342-1349
pubmed: 30779728
Arch Biochem Biophys. 2019 Jan;661:196-202
pubmed: 30468709
Med Sci Monit. 2019 Aug 28;25:6454-6461
pubmed: 31456594
Cancer Biomark. 2016;16(1):161-9
pubmed: 26600397
Front Oncol. 2021 Jul 02;11:697747
pubmed: 34277444
Cell Death Dis. 2020 Dec 14;11(12):1065
pubmed: 33311442
Cancer Cell Int. 2020 Aug 18;20:400
pubmed: 32831653
Biochem Biophys Res Commun. 2018 Mar 4;497(2):626-632
pubmed: 29458020
Liver Cancer. 2021 Sep 22;10(6):593-605
pubmed: 34950182
J Huazhong Univ Sci Technolog Med Sci. 2017 Dec;37(6):886-890
pubmed: 29270748
Biomedicines. 2022 May 11;10(5):
pubmed: 35625853
IUBMB Life. 2021 Jan;73(1):159-176
pubmed: 33220169
Oncotarget. 2017 Jul 18;8(29):48169-48177
pubmed: 28636993
Circ Res. 2015 Oct 23;117(10):884-90
pubmed: 26377962
Cell Death Dis. 2021 Dec 20;13(1):12
pubmed: 34930906
CNS Neurol Disord Drug Targets. 2022 Aug 29;:
pubmed: 36043720
Cell Death Dis. 2017 Nov 16;8(11):e3171
pubmed: 29144509
Eur Rev Med Pharmacol Sci. 2020 Dec;24(23):12124-12130
pubmed: 33336730
Front Oncol. 2021 Feb 17;10:608257
pubmed: 33680930
Eur J Pharmacol. 2023 Jul 5;950:175755
pubmed: 37119959
Biomed Pharmacother. 2021 Oct;142:112025
pubmed: 34392090
Cancer Res Treat. 2016 Jul;48(3):1065-73
pubmed: 26511806
Int J Mol Sci. 2015 Aug 10;16(8):18564-79
pubmed: 26266404
Cancer Res. 2006 Dec 15;66(24):11851-8
pubmed: 17178882
RNA. 2019 Jan;25(1):1-16
pubmed: 30333195
Front Oncol. 2019 Jul 10;9:584
pubmed: 31355135
Nat Rev Cancer. 2002 Jan;2(1):38-47
pubmed: 11902584
Adv Exp Med Biol. 2018;1087:67-79
pubmed: 30259358
Front Immunol. 2019 Apr 02;10:639
pubmed: 31001261
Oncol Lett. 2019 Feb;17(2):2091-2098
pubmed: 30675276
Front Pharmacol. 2023 Apr 19;14:1152672
pubmed: 37153758
J BUON. 2018 Jul-Aug;23(4):971-978
pubmed: 30358201
Cancer Cell Int. 2020 Sep 14;20:454
pubmed: 32944002
J Cell Physiol. 2018 Jun;233(6):4408-4422
pubmed: 28833094
Organogenesis. 2008 Apr;4(2):68-75
pubmed: 19279717
Gut Liver. 2016 Sep 15;10(5):826-35
pubmed: 27282266
Nat Cell Biol. 2010 May;12(5):468-76
pubmed: 20418870
Dig Liver Dis. 2019 Oct;51(10):1446-1455
pubmed: 31147216
Mol Med Rep. 2016 Jun;13(6):4865-71
pubmed: 27081789
World J Gastrointest Oncol. 2010 Sep 15;2(9):348-59
pubmed: 21160806
Mol Cancer. 2020 Nov 23;19(1):163
pubmed: 33222692
Cell Prolif. 2021 Mar;54(3):e12981
pubmed: 33458917
Cancer Biol Ther. 2018;19(12):1139-1152
pubmed: 30207869
Cell Biochem Funct. 2020 Aug;38(6):686-694
pubmed: 32232872
J Cell Biochem. 2019 Jul;120(7):11350-11357
pubmed: 30719761
Front Cell Dev Biol. 2023 Jan 10;10:1082657
pubmed: 36704201
Front Cell Dev Biol. 2021 Jul 21;9:709512
pubmed: 34368160
Anticancer Res. 2017 Aug;37(8):4337-4343
pubmed: 28739726
J Biol Chem. 2009 Jul 31;284(31):20629-37
pubmed: 19520846
Biomed Pharmacother. 2023 Mar;159:114260
pubmed: 36657303
Biochem Biophys Res Commun. 2018 Sep 3;503(1):56-61
pubmed: 29842886
J Exp Clin Cancer Res. 2014 Dec 11;33:107
pubmed: 25499541
Cell Death Dis. 2019 Jul 11;10(7):536
pubmed: 31296839
Surg Oncol. 2016 Jun;25(2):74-85
pubmed: 27312032
Cell Signal. 2019 Aug;60:122-135
pubmed: 31028816
Mol Cell. 2015 Jun 4;58(5):870-85
pubmed: 25921068
Genes Dis. 2023 Mar 24;11(1):103-134
pubmed: 37588235
DNA Cell Biol. 2020 Jan;39(1):118-125
pubmed: 31859543
Cancer Manag Res. 2020 Aug 06;12:6987-6998
pubmed: 32821165
Oncotarget. 2015 Mar 20;6(8):6001-13
pubmed: 25749389
Int J Mol Sci. 2017 Feb 21;18(2):
pubmed: 28230774
Front Oncol. 2021 Apr 13;10:596623
pubmed: 33928018
Respir Res. 2017 Sep 5;18(1):167
pubmed: 28870231
Oncotarget. 2016 Nov 15;7(46):75394-75406
pubmed: 27683117
Clin Transl Oncol. 2020 Dec;22(12):2293-2302
pubmed: 32472455
Biochem Biophys Res Commun. 2018 Feb 5;496(2):455-461
pubmed: 29337065
Oxid Med Cell Longev. 2021 Jan 4;2021:7689045
pubmed: 33488943
Methods Mol Biol. 2008;469:3-18
pubmed: 19109698
Biomed Res Int. 2016;2016:1579490
pubmed: 27642589
Mol Cell Biol. 2012 Oct;32(19):3903-12
pubmed: 22826439
Oncogene. 2017 Oct 26;36(43):6020-6029
pubmed: 28671671
J Biol Chem. 2003 Aug 29;278(35):33422-35
pubmed: 12816952
Cancers (Basel). 2020 Dec 05;12(12):
pubmed: 33291485
RNA. 2013 Feb;19(2):141-57
pubmed: 23249747
J Cancer Res Clin Oncol. 2017 Jan;143(1):17-27
pubmed: 27614453
Mol Cancer. 2022 May 5;21(1):108
pubmed: 35513849
Cell Mol Biol Lett. 2022 Jan 15;27(1):7
pubmed: 35033019
Onco Targets Ther. 2019 Nov 11;12:9539-9549
pubmed: 31807029
Cancer Manag Res. 2020 May 26;12:3915-3925
pubmed: 32547227
Cell Physiol Biochem. 2018;51(1):470-486
pubmed: 30453289
Neoplasma. 2019 Mar 5;66(2):232-239
pubmed: 30509108
Genome Biol. 2019 Apr 26;20(1):84
pubmed: 31027518
Cancer Biol Ther. 2019;20(8):1127-1135
pubmed: 30975029
Nat Rev Genet. 2019 Nov;20(11):675-691
pubmed: 31395983
Clin Sci (Lond). 2019 May 30;133(10):1197-1213
pubmed: 31109967
Exp Biol Med (Maywood). 2020 Mar;245(5):411-426
pubmed: 31996036
F1000Res. 2020 Aug 6;9:
pubmed: 32802314
Biomedicines. 2022 Mar 21;10(3):
pubmed: 35327527
Reprod Sci. 2019 Aug;26(8):1071-1081
pubmed: 30309296
Pathol Res Pract. 2021 Nov;227:153618
pubmed: 34649056
Am J Cancer Res. 2016 Jun 01;6(6):1167-76
pubmed: 27429839
Int J Mol Sci. 2022 Feb 12;23(4):
pubmed: 35216159
Cell Mol Biol Lett. 2022 Aug 3;27(1):65
pubmed: 35922753
Signal Transduct Target Ther. 2022 Jan 3;7(1):3
pubmed: 34980884
Front Cell Dev Biol. 2022 Jul 06;10:900418
pubmed: 35874827
Yakugaku Zasshi. 2020;140(5):687-700
pubmed: 32378673
Cancer Cell Int. 2020 Jul 8;20:295
pubmed: 32669971
Medicine (Baltimore). 2016 May;95(22):e3811
pubmed: 27258521
Sci Rep. 2020 Oct 15;10(1):17443
pubmed: 33060778
Theranostics. 2019 May 26;9(12):3526-3540
pubmed: 31281495
Mol Ther Nucleic Acids. 2020 Oct 04;22:750-765
pubmed: 33230473
Eur J Pharmacol. 2014 Oct 5;740:364-78
pubmed: 25058905
Eur Rev Med Pharmacol Sci. 2018 Dec;22(23):8203-8209
pubmed: 30556859
J Hematol Oncol. 2020 Dec 4;13(1):165
pubmed: 33276800
Front Mol Biosci. 2017 Jun 06;4:38
pubmed: 28634583